ABL Bio inks $1.06-billion deal with Sanofi for Parkinson's treatment
ABL Bio has inked a technology transfer deal worth up to $1.06 billion with Paris-based Sanofi for ABL301, its treatment candidate for degenerative brain diseases such as Parkinson’s disease, the Kosdaq-listed company said Wednesday.